Theriva Biologics (TOVX) posted a first quarter net loss to stockholders of $4.3 million compared to a loss of $5.2 million, prior year. Net loss per share was $1.55 compared to a loss of $7.53. Cash and cash equivalents were $10 million as of March 31, 2025, compared to $11.6 million as of December 31, 2024.
Steven Shallcross, CEO of Theriva Biologics, said: "The VIRAGE Phase 2b clinical trial of VCN-01 with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients achieved its primary survival and safety endpoints. We are working to scale up manufacturing and finalize the design of a Phase 3 trial of VCN-01 with gemcitabine/nab-paclitaxel."
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.